Cambridge Biotech Corp. (NASDAQ:CBCX) announced that it isseeking to withdraw its $100 million shelf registrationstatement with the Securities and Exchange Commission thatwas filed Dec. 3, 1992.
"The shelf registration led people to believe that a large publicoffering was contemplated in the near term," said PeterHartman, vice president of finance and chief financial officer."This was never the company's intention. Our intent was toutilize revised SEC shelf registration rules in order to be readyfor possible offerings over the next two years. For avoidance ofdoubt, withdrawing this registration is in the company's bestinterest."
Cambridge Biotech of Worcester, Mass., is a diagnostics andvaccine company involved in applications for humans andanimals.
(c) 1997 American Health Consultants. All rights reserved.